Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1522764

	registered interest
	date	17/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Voluntary scheme for branded medicines pricing and access, whether her Department has made an assessment of the potential merits of an exemption from payments for new active substances from that scheme.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	64035
	answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>The Voluntary Scheme for Branded Medicines Pricing and Access includes a 36 month exemption from payments for drugs containing a new active substance, starting once the marketing authorisation has been granted. Treatment of new active substances under a future voluntary scheme is subject to negotiation.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 16:47:32 answering member 4320 label Biography information for Robert Jenrick
	tabling member	3985 label Biography information for Robert Halfon

1521780

	registered interest
	date	13/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many medicine by presentations included within the Voluntary Patient Access Scheme have had NHS List Price increase approved by their Department since 1 January 2020; and what was the average percentage increase for any such increases.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	62789
	answer	answer is ministerial correction date of answer 03/11/2022 answer text <p>Between 1 January 2020 and 14 October 2022, members of the Voluntary Scheme for Branded Medicines Pricing and Access have received approval for an increase to the National Health Service list price for 35 medicines, for 120 presentations. The majority of price increases have been concentrated in specific market segments particularly impacted by global cost increases in the active pharmaceutical ingredient.</p><p>Price increase requests are assessed in line with Scheme’s rules, which ensure companies cannot make excess profits by setting a return on sales target of 6% for standard price increase requests.</p> answering member constituency Colchester answering member printed Will Quince question first answered 03/11/2022 13:28:21 answering member 4423 label Biography information for Will Quince
	tabling member	3985 label Biography information for Robert Halfon

1521782

	registered interest
	date	13/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans her Department has to carry out an impact assessment on the effect of an increased voluntary scheme for branded medicine rate to a projected 23.7 per cent in 2023 upon the supply of medicines to the NHS.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	62790
	answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>The Department has no plans to carry out an impact assessment on the 2023 payment percentage. The Department’s standard practice is to set the payment percentage based on measured sales. The payment percentage projected for 2023 is in line with Department projections shared with industry when the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) was agreed.</p><p>We have seen no evidence that increased VPAS payments have or will impact on the supply of medicines to the National Health Service. Where payment rates may put pressure on the profitability of individual products, there are provisions in the scheme for companies to apply for a price increase.</p> answering member constituency Colchester answering member printed Will Quince question first answered 01/11/2022 12:16:12 answering member 4423 label Biography information for Will Quince
	tabling member	3985 label Biography information for Robert Halfon

1521787

	registered interest
	date	13/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to publish data comparing the voluntary scheme for branded medicines pricing and access repayments against leading European countries with similar access or rebate schemes in each year since 2015.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	62791
	answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>We have no plans to do so.</p><p>Prices paid for medicines internationally are generally confidential. It is therefore not possible to make an accurate comparison of the net price of medicines between the UK and other countries, with or without rebate rates.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 14:51:43 answering member 4320 label Biography information for Robert Jenrick
	tabling member	3985 label Biography information for Robert Halfon

1521788

	registered interest
	date	13/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, for what reason her Department included branded (a) generic and (b) biosimilar medicines that delivered savings to the NHS within the current voluntary scheme for branded medicines pricing and access scheme.
	tabling member constituency	Harlow
	tabling member printed	Robert Halfon
	uin	62792
	answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>Medicines which are required to be prescribed by brand name, including some branded generics and biosimilars, are not interchangeable. Therefore, competitive forces will not act in the same way as for generic medicines and price regulation is justified. The inclusion of these medicines in the Voluntary Scheme for Branded Medicines Pricing and Access was agreed with industry in 2019.</p> answering member constituency Colchester answering member printed Will Quince question first answered 01/11/2022 12:23:25 answering member 4423 label Biography information for Will Quince
	tabling member	3985 label Biography information for Robert Halfon